Comparative Pharmacology
Head-to-head clinical analysis: MANNITOL 10 versus OSMITROL 15 IN WATER IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MANNITOL 10 versus OSMITROL 15 IN WATER IN PLASTIC CONTAINER.
MANNITOL 10% vs OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mannitol is an osmotic diuretic that increases urinary output by raising the osmolarity of glomerular filtrate, thereby reducing tubular reabsorption of water and solutes. It also reduces cerebral edema by creating an osmotic gradient across the blood-brain barrier, drawing water from brain tissue into plasma.
Osmotically active agent that increases plasma osmolality, drawing water from intracellular and interstitial spaces into the vascular compartment, thereby reducing cerebral edema and intraocular pressure.
0.25-2 g/kg intravenously as a 10% solution over 30-60 minutes, typically 50-100 g every 6-8 hours.
1.5-2 g/kg intravenous infusion over 30-60 minutes every 6-8 hours as needed for reduction of intracranial pressure or cerebral edema.
None Documented
None Documented
Terminal half-life: 1.1–1.6 hours; prolonged to 6–36 hours in renal impairment
Terminal half-life: 0.25–1.5 hours (15–90 minutes) in normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Renal: 90% as unchanged drug; <10% metabolized in liver to fructose and glucose; fecal: negligible
Renal: >90% unchanged by glomerular filtration; minimal tubular reabsorption or secretion. <10% metabolized in liver (negligible).
Category A/B
Category C
Osmotic Diuretic
Osmotic Diuretic